Lead Sponsor

Eli Lilly and Company

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Have ED-SCLC and have received a prior platinum-based regimen
•Participants in Cohort 1 and in the addendum must have had an objective response to prior platinum-based therapy with subsequent progression ≥90 days after the last dose of platinum
•Participants in Cohort 2 must have either not had an objective response to prior platinum based therapy or had progression \<90 days after the last dose of platinum
•Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group scale

•Have received more than 2 prior therapies for ED-SCLC (including immunotherapy, targeted therapies, or chemotherapy)
•Have symptomatic central nervous system (CNS) malignancy or metastasis. Asymptomatic participants with treated CNS metastases are eligible for this study if they are not currently receiving corticosteroids to treat CNS metastases
•Have previously completed or withdrawn from this study or any other study investigating prexasertib or a checkpoint kinase I (CHK1) inhibitor or have shown hypersensitivity to any of the components of the prexasertib formulation
•Have a serious cardiac condition

Related studies

NCT06312137 · Non Small Cell Lung Cancer

NCT07444437 · Non-Small Cell Lung Cancer

NCT07489716 · Non-Small Cell Lung Cancer

NCT07300150 · Colorectal Cancer, Pancreatic Cancer, and more

NCT07154290 · Advanced/Metastatic Non-Small Cell Lung Cancer

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer